louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05506800: Guangzhou Women's Health Cohort Study (GWHCS)
Official title: Guangzhou Women's Health Cohort Study (GWHCS)
Study type: OBSERVATIONAL
Overall status: SUSPENDED
Conditions: Cervical Cancer
Breast Cancer
Lung Cancer
Colorectal Cancer
Endometrial Cancer
Ovarian Cancer
Hypertension
Diabetes
Reproductive Disorder
Lead sponsor: Guangzhou Women and Children's Medical Center
Sponsor class: OTHER
First posted: 2022-08-18
Enrollment: 1000000
Sex: FEMALE
Minimum age (years): 35
Maximum age (years): 64
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Women aged 35-64 years old with registered permanent residence in Guangzhou

Brief summary: The Guangzhou Women's Health Cohort Study aims to explore the health trajectory and factors contributing to the health of women aged 35-64 in Guangzhou. Based on multiple population health registration data platforms, data of the cohort will provide information about the health of women across the lifespan, facilitating the decision-making process by local government . The cohort is progressing steadily, and the goal is to build a large women cohort covering 11 administrative districts of Guangzhou with a scale of 1 million by 2030.

Detailed description: The Guangzhou Women's Health Cohort Study aims to explore the health trajectory and factors contributing to the health of women aged 35-64 in Guangzhou. Based on multiple population health registration data platforms, data of the cohort will provide information about the health of women across the lifespan, facilitating the decision-making process by local government . The cohort is progressing steadily, and the goal is to build a large women cohort covering 11 administrative districts of Guangzhou with a scale of 1 million by 2030.

Eligibility criteria: Inclusion Criteria:

* Women aged 35-64 years old
* Women with registered permanent residence in Guangzhou
* Women with informed consent

Exclusion Criteria:

* Women without informed consent
* Women with reading and/or writing difficulties
* Women with serious mental disorders

Primary outcomes:
measure: Incidence and mortality rate of cancer
timeFrame: through study completion, an average of 2 years
Secondary outcomes:
measure: Hypertension and diabetes
timeFrame: through study completion, an average of 2 years
measure: Reproductive health
timeFrame: through study completion, an average of 2 years
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: Guangzhou Women and Children's Medical Center
state: Guangdong
Study officials:
affiliation: Guangzhou Women and Children's Medical Center, China
name: Xiu Qiu, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02654600: Variations of the Lung Compliance During Extracorporeal Circulation and Post Operative Pulmonary Complications
Official title: Variations of the Lung Compliance During Extracorporeal Circulation and Post Operative Pulmonary Complications
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Thoracic Surgery
Cardiopulmonary Bypass
Keywords: cardiac surgery
thoracopulmonary compliance
Lead sponsor: Centre Chirurgical Marie Lannelongue
Sponsor class: OTHER
First posted: 2016-01-13
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Every ASA 2 or 3 patient eligible for non-complex and non-urgent cardiac surgery

Brief summary: the decrease in thoracopulmonary compliance after cardiac surgery is well known . The investigators hypothesize that the major factor determining pulmonary outcome after cardiac surgery is the alteration of pulmonary compliance during cardiopulmonary bypass(CBP) and that this alteration is due to CBP itself through pulmonary blood emptying.

Detailed description: compliance is the compliance calculate when thorax is closed, the pulmonary compliance is the compliance calculated when thorax is opened After operation chest X-ray are daily done and blood samples as needed. Were recorded death, time of extubation,duration of non invasive ventilation,of Intensive Care Unit stay and of total hospital stay, troponin peak, lactates, blood gases, ionogram and count.Variations of compliance is analyzed through one factor paired Anova or Wilcoxon paired test. Decrease of compliance and respiratory complications are analyzed through binomial logistic regression.

Eligibility criteria: Inclusion Criteria:

* scheduled for standard aortic
* mitral or coronary surgery

Exclusion Criteria:

* emergency operation
* no complete preoperative echocardiography
* surgery needing multiple table position changes
* unstable cardiac or respiratory condition
* difficult patient needing multiple care and/or special attention

Primary outcomes:
measure: pulmonary compliance during cardiac surgery
timeFrame: intraoperative
Secondary outcomes:
measure: pulmonary complications including death after cardiac surgery
timeFrame: 1 month
measure: thoracopulmonary compliance during cardiac surgery
timeFrame: intraoperative
Other outcomes:
Locations:
city: Le Plessis Robinson
country: France
facility: Centre Chirurgical Marie Lannelongue
Study officials:
References:
citation: Ellison LT, Duke JF 3rd, Ellison RG. Pulmonary compliance following open-heart surgery and its relationship to ventilation and gas exchange. Circulation. 1967 Apr;35(4 Suppl):I217-25. doi: 10.1161/01.cir.35.4s1.i-217. No abstract available.
citation: Suter PM, Fairley HB, Isenberg MD. Effect of tidal volume and positive end-expiratory pressure on compliance during mechanical ventilation. Chest. 1978 Feb;73(2):158-62. doi: 10.1378/chest.73.2.158.
Clinical trial NCT06150300: Examining the Effects of a Remote Pulmonary Rehabilitation Program in the Severe Asthma Population.
Official title: STAPLE (Severe asThmA PuLmonary rEhab): Examining the Effects of a Remote Pulmonary Rehabilitation Program in the Severe Asthma Population.
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Asthma
Lead sponsor: University of Saskatchewan
Sponsor class: OTHER
First posted: 2023-11-29
Enrollment: 34
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a randomized control trial evaluating the effect of a novel mobile application-delivered pulmonary rehabilitation program in adult severe asthma patients. The intervention will include eight weeks of exercise videos that progress in difficulty, as well as asthma-specific educational content. The primary outcome measure is change in functional exercise capacity as measured by six-minute walk distance. Secondary outcome measures will include evaluation of overall feasibility, and change in CPET parameters such as VO2max. Change in asthma control questionnaire (ACQ), asthma quality of life questionnaire (AQLQ) and PRAISE self-efficacy score will also be evaluated.


Eligibility criteria: Inclusion Criteria:

* Adults aged 18 years and older with a diagnosis of asthma by a respirologist. They must have severe disease defined by GINA severity classification. Participants must have access to a smartphone or internet browser to allow access to study content.

Exclusion Criteria:

* Exclusion criteria include comorbid cardiopulmonary or musculoskeletal conditions that may impact exercise tolerance in accordance with the American Thoracic Society CPET guidelines

Primary outcomes:
measure: CPET
timeFrame: After 8 weeks of intervention
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00954200: Ibuprofen as a Possible Preventer of Post Bronchoscopy Fever
Official title: Ibuprofen as a Possible Preventer of Post Bronchoscopy Fever
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Post Bronchoscopy Fever
Lead sponsor: Shaare Zedek Medical Center
Sponsor class: OTHER
First posted: 2009-08-07
Enrollment: 64
Sex: ALL
Maximum age (years): 12
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Scientific background: Bronchoscopy is a procedure commonly performed in the management of persistent respiratory illness. In the last decades this exam has become a routine and safe procedure even in children and there are few side-effects. However, one known side effect is transient fever and even high fever a few hours after the bronchoscopy. This side effect is not dangerous but very uncomfortable for the patients and it would be interesting to try to reduce this phenomena. This fever is due to a release of cytokines during the broncho-alveolar lavage procedure and not to sepsis. In a previous study a single dose of dexamethasone was shown to prevent the fever post bronchoscopy with no apparent detriment to the child. It is well known that steroids are immunosuppressive. Even though the post-bronchoscopy fever is not caused by an infection, it seems preferable to use other anti-inflammatory drugs to fight this very inconvenient side effect.

Ibuprofen (Nurofen\*) is known as an effective medication to reduce fever in infectious illnesses and is even considered as superior to paracetamol. It has no immunosuppressive effect and is usually well tolerated by children with very few side effects when taken in the normal therapeutic dose of 10mg/Kg. The investigators postulate that a dose of Nurofen prior to bronchoscopy could significantly reduce fever post bronchoscopy.


Eligibility criteria: Inclusion Criteria:

* under twelve years of age
* all patients undergoing bronchoscopy and bronchoalveolar lavage

Exclusion Criteria:

* children with immune deficiency
* allergy to NSAIDS
* previous exacerbation of asthma due to NSAIDS
* fever on the day of the examination
* current antibiotic treatment

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Jerusalem
country: Israel
facility: Shaare Zedek Medical Center POB 3235
city: Jerusalem
country: Israel
facility: Shaare Zedek Medical Center
Study officials:
References:
citation: Picard E, Schwartz S, Goldberg S, Glick T, Villa Y, Kerem E. A prospective study of fever and bacteremia after flexible fiberoptic bronchoscopy in children. Chest. 2000 Feb;117(2):573-7. doi: 10.1378/chest.117.2.573.
citation: Fonseca MT, Camargos PA, Abou Taam R, Le Bourgeois M, Scheinmann P, de Blic J. Incidence rate and factors related to post-bronchoalveolar lavage fever in children. Respiration. 2007;74(6):653-8. doi: 10.1159/000107737. Epub 2007 Aug 29.
Clinical trial NCT00598000: Quality of Life and Pain Outcomes Following Video-Assisted Thoracic Surgery (VATS) Anatomic Lung Resection Versus Thoracotomy and Anatomic Lung Resection
Official title: Quality of Life and Pain Outcomes Following Video-Assisted Thoracic Surgery (VATS) Anatomic Lung Resection Versus Thoracotomy and Anatomic Lung Resection
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Lung Cancer
Quality of Life
Video-assisted Thoracic Surgery (VATS)
Thoracotomy
Keywords: Lung cancer
Quality of Life
VATS
thoracotomy
05-006
Lead sponsor: Memorial Sloan Kettering Cancer Center
Sponsor class: OTHER
First posted: 2008-01-18
Enrollment: 216
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: MSKCC Clinics

Brief summary: The purpose of this study is to see if different types of surgery for lung cancer have different effects on quality of life and pain. What we learn from this study may help us find new ways to improve the quality of life of lung cancer patients who have surgery.


Eligibility criteria: Inclusion Criteria:

* Patients with histologically confirmed or suspected clinical stage I non small cell lung cancer (including carcinoid tumors) based on standard staging (CT, PET, ± mediastinoscopy).
* Patients offered a VATS anatomic lung resection or a standard, posterolateral thoracotomy and anatomic lung resection at MSKCC.
* Patients cannot have had prior therapy, including surgery for the current lesion, systemic chemotherapy or external beam radiotherapy.
* KPS ≥ 70.
* Synchronous primaries within one lobe.

Exclusion Criteria:

* Patients who have already undergone the planned operation.
* Patients who cannot tolerate segmentectomy or lobectomy.
* Patients with locally advanced or metastatic disease found either preoperatively or at the time of operation.
* Patients who are non- English speaking
* Patients with multi-focal disease
* Patients with con-current cancers
* Patients with benign disease.
* Patients who are unwilling or unable to return to Memorial Sloan-Kettering Cancer Center for postoperative follow-up for the first year following their operation.

Primary outcomes:
measure: Determine the postoperative change in QOL and level of pain in patients with clinical stage I NSCLC undergoing VATS anatomic lung resection and for patients with clinical stage I NSCLC undergoing thoracotomy and anatomic lung resection
timeFrame: conclusion of study
Secondary outcomes:
measure: Compare early postoperative analgesic requirements between the VATS and thoracotomy groups.
timeFrame: conclusion of study
Other outcomes:
Locations:
city: New York
country: United States
facility: Memorial Sloan Kettering Cancer Center
state: New York
Study officials:
affiliation: Memorial Sloan Kettering Cancer Center
name: Nabil Rizk, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00100100: Modafinil for the Treatment of Cocaine Dependence - 1
Official title: Modafinil for the Treatment of Cocaine Dependence
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Cocaine-Related Disorders
Keywords: cocaine dependence
Lead sponsor: National Institute on Drug Abuse (NIDA)
Sponsor class: NIH
First posted: 2004-12-23
Enrollment: 210
Sex: ALL
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Primary purpose: DIAGNOSTIC

Brief summary: The purpose of this study is to evaluate the efficacy and safety of modafinil in reducing cocaine use in subjects with cocaine dependence.

Detailed description: This is a double-blind, placebo-controlled, parallel group design study to evaluate the efficacy and safety of modafinil in reducing cocaine use in subjects with cocaine dependence.

Eligibility criteria: Inclusion Criteria:

* Participant must have DSM-IV diagnosis of cocaine dependence as determined by SCID.
* Must be seeking treatment for cocaine dependence.
* Must be able to understand and provide written informed consent.

Exclusion Criteria:

* Please contact the study site for more information.

Primary outcomes:
measure: Cocaine abstinence
Secondary outcomes:
Other outcomes:
Locations:
city: Boston
country: United States
facility: Boston University Medical Center
state: Massachusetts
city: New York
country: United States
facility: New York VA Medical Center
state: New York
city: Cincinnati
country: United States
facility: Cincinnati Addiction Research Center
state: Ohio
city: Pittsburgh
country: United States
facility: Western Psychiatric Institute & Clinic
state: Pennsylvania
city: Dallas
country: United States
facility: RHD Professional Plaza 4
state: Texas
city: San Antonio
country: United States
facility: UTHSCSA
state: Texas
Study officials:
affiliation: Boston University
name: Domenic Ciraulo, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05850000: Discovering Factors in the Clinical Trial Journey of Dementia Patients
Official title: Dementia Clinical Trials: A Study on the Clinical Trial Participation of Dementia Patients
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Dementia
Keywords: dementia
Lead sponsor: Power Life Sciences Inc.
Sponsor class: INDUSTRY
First posted: 2023-05-09
Enrollment: 500
Sex: ALL
Minimum age (years): 55
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CROSSOVER
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients with dementia who are actively considering involvement in an observational clinical trial, but have not yet completed enrollment and registration.

Brief summary: This research aims to collect comprehensive data on the clinical trial experience of dementia patients. Its goal is to identify the factors that limit patients' ability to join or complete a trial successfully. Clinical trial participation often favors specific demographic groups, and limited research exists on the impact of trial attributes on participation. Therefore, this study aims to analyze data from various demographic groups and identify any recurring trends that could provide valuable insights for future dementia patients.


Eligibility criteria: Inclusion Criteria:

* Ability to provide written informed consent obtained prior to participation in the study and any related procedures being performed.
* Participant has a diagnosis of dementia.
* Willing and able to comply with scheduled visits, treatment schedule, laboratory tests and other requirements of the study.

Exclusion Criteria:

* Pregnant or lactating woman
* Enrolled in another research study
* Any mental or medical condition that prevents the patient from giving informed consent or participating in the trial

Primary outcomes:
measure: Rate of patients who decide to enroll in a dementia clinical study.
timeFrame: 3 months
measure: Number of dementia patients who remain in clinical trial until completion.
timeFrame: 12 months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Power Life Sciences Inc.
name: Michael B Gill
role: STUDY_DIRECTOR
References:
citation: Perng CH, Chang YC, Tzang RF. The treatment of cognitive dysfunction in dementia: a multiple treatments meta-analysis. Psychopharmacology (Berl). 2018 May;235(5):1571-1580. doi: 10.1007/s00213-018-4867-y. Epub 2018 Mar 3.
citation: Whitehouse PJ, Kittner B, Roessner M, Rossor M, Sano M, Thal L, Winblad B. Clinical trial designs for demonstrating disease-course-altering effects in dementia. Alzheimer Dis Assoc Disord. 1998 Dec;12(4):281-94. doi: 10.1097/00002093-199812000-00007.
citation: Graham NS, Sharp DJ. Understanding neurodegeneration after traumatic brain injury: from mechanisms to clinical trials in dementia. J Neurol Neurosurg Psychiatry. 2019 Nov;90(11):1221-1233. doi: 10.1136/jnnp-2017-317557. Epub 2019 Sep 21.
Clinical trial NCT01491100: Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis
Official title: Study Assessing Cognitive Performance Plus Physical Activity in Patients With Relapsing-Remitting MS Under Treatment With Betaferon®
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Multiple Sclerosis
Keywords: Cognition
Physical Activity
Relapsing Remitting Multiple Sclerosis
Lead sponsor: Bayer
Sponsor class: INDUSTRY
First posted: 2011-12-13
Enrollment: 1085
Sex: ALL
Minimum age (years): 12
Maximum age (years): 70
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Community Sample

Brief summary: Study assessing cognitive function and physical activity in people with relapsing remitting multiple sclerosis.


Eligibility criteria: Inclusion Criteria:

* Patients with Relapsing Remitting Multiple Sclerosis (RRMS), and treated with Betaferon, with the decision for treatment made at the discretion of the attending physician, documented with a prescription of Betaferon by the physician
* EDSS 0 - 6
* Written informed consent

Exclusion Criteria:

* Patients who do not meet the local indication criteria for Betaferon treatment.
* Contraindications listed in the local SmPCs have to be considered.
* Patients with a history of severe head trauma.
* Patients with alcohol and/or drug abuse.
* Patients with mental retardation.
* Patients with learning disability.

Primary outcomes:
measure: Cognitive performance as measured by SDMT (Symbol Digit Modalities Test)
timeFrame: 24 months
measure: Physical activity as measured by the Baecke questionnaire
timeFrame: 24 months
Secondary outcomes:
measure: Disability as measured by EDSS (Expanded Disability Status Scale)
timeFrame: 24 months
measure: Fatigue as measured by FSMC (Fatigue Scale for Motor and Cognitive Functions)
timeFrame: 24 months
measure: Depression as measured by the CES-D (Center for Epidemiologic Studies Depression)
timeFrame: 24 months
measure: Quality of life as measured by the SF-12 (Mental and physical health-scale measure of quality of life)
timeFrame: 24 months
Other outcomes:
Locations:
city: Multiple Locations
country: Albania
city: Multiple Locations
country: Algeria
city: Multiple Locations
country: Argentina
city: Multiple Locations
country: Belgium
city: Multiple Locations
country: Czechia
city: Multiple Locations
country: Egypt
city: Multiple Locations
country: France
city: Multiple Locations
country: Germany
city: Multiple Locations
country: Greece
city: Multiple Locations
country: Hungary
city: Multiple Locations
country: Israel
city: Multiple Locations
country: Kazakhstan
city: Multiple Locations
country: Netherlands
city: Multiple Locations
country: Portugal
city: Multiple Locations
country: Saudi Arabia
city: Multiple Locations
country: Tunisia
city: Multiple Locations
country: Turkey
Study officials:
affiliation: Bayer
name: Bayer Study Director
role: STUDY_DIRECTOR
References: